ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2287

Evaluation of the Fibromyalgia Rapid Screening Tool (FiRST) Questionnaire to Screen Fibromyalgia Associated with Inflammatory Rheumatic Disease

Angélique Fan1, Bruno Pereira2, Anne Tournadre3, Zuzana Tatar1, Sandrine Malochet-Guinamand4, Martin Soubrier1 and Jean-Jacques Dubost1, 1Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 2Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, 3Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 4Rheumatology Department,, Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Evaluation, fibromyalgia, questionnaires and rheumatic disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Fibromyalgia (FM) is prevalent in patients with chronic inflammatory rheumatic diseases (CIRd), where it hampers diagnosis and activity assessment. No tool for screening FM associated with CIRd has ever been evaluated. The Fibromyalgia Rapid Screening Tool (FiRST) is a brief and simple self-complete questionnaire that has been validated for screening FM in patients with diffuse chronic pain. The purpose of this study was to evaluate how well FiRST performs on screening for FM associated with CIRd.

Methods: This single-center cross-sectional study was conducted between September 2014 and April 2015 on all patients with chronic pain presenting for rheumatoid arthritis (RA), spondyloarthritis (SpA), and connective tissue disease (Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE), scleroderma (Scl), myositis). Diagnosis of FM was based on ACR–90 classification criteria (to minimize interfering overlap between rheumatic disease-related pain and FM-related pain) and expert opinion.

Results: The population included 605 patients: 279 RA, 271 SpA (52 psoriatic arthritis, 126 radiographic axial SpA, 64 non-radiographic axial SpA, 29 peripheral SpA), 57 connective tissue disease. In total, 51 patients had FM meeting the ACR–90 criteria, and 93 patients were given a diagnosis of FM by the expert. When tested against the ACR–90 classification criteria, FiRST demonstrated a sensitivity of 74.5%, a specificity of 80.4%, a positive predictive value of 26.6% and a negative predictive value of 97.1%. Specificity was significantly weaker in the connective tissue disease group (RA: 84.4%, SpA: 80.2%, connective tissue disease: 59.6%; p<0.001). When tested against expert opinion, FiRST demonstrated a sensitivity of 75.8%, a specificity of 85.1%, a positive predictive value of 48.3% and a negative predictive value of 95%. FiRST underperformed on sensitivity in the SpA group compared to the connective tissue disease group (66% vs 94.4%; p=0.004). Performances varied according to item in the self-complete questionnaire.

Conclusion: The symptoms of rheumatic disease interfere with the symptoms of fibromyalgia. FiRST nevertheless manages to perform well in this population, showing an excellent negative predictive value.


Disclosure: A. Fan, None; B. Pereira, None; A. Tournadre, None; Z. Tatar, None; S. Malochet-Guinamand, None; M. Soubrier, None; J. J. Dubost, None.

To cite this abstract in AMA style:

Fan A, Pereira B, Tournadre A, Tatar Z, Malochet-Guinamand S, Soubrier M, Dubost JJ. Evaluation of the Fibromyalgia Rapid Screening Tool (FiRST) Questionnaire to Screen Fibromyalgia Associated with Inflammatory Rheumatic Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-the-fibromyalgia-rapid-screening-tool-first-questionnaire-to-screen-fibromyalgia-associated-with-inflammatory-rheumatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-the-fibromyalgia-rapid-screening-tool-first-questionnaire-to-screen-fibromyalgia-associated-with-inflammatory-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology